Myozyme Effectiveness in LOPD Fades Over Time, Real-world Study Finds

Myozyme Effectiveness in LOPD Fades Over Time, Real-world Study Finds

288596

Myozyme Effectiveness in LOPD Fades Over Time, Real-world Study Finds

In the first years of treatment, Myozyme (alglucosidase alfa) — marketed in the U.S. as Lumizyme — can effectively increase physical endurance, and improve lung function and muscle strength in adults with late-onset Pompe disease (LOPD), a real-world study found. Yet, despite this treatment, patients’ clinical outcomes, particularly lung function, tend to deteriorate over time, indicating that additional efforts must be made to improve Myozyme’s effectiveness. These findings were reported in “STIG study: real-world data of…

You must be logged in to read/download the full post.